Can-Fite Biopharma Ltd.’s namodenoson met the safety endpoint in its phase IIa open-label study in advanced pancreatic ductal adenocarcinoma patients, a readout that left investors hopeful for survival data, expected to be disclosed later this year.
In a recent paper, researchers from the University of Perugia and University of Naples Federico II have shown how the use of leukemia inhibitory factor receptor (LIFR) antagonists dismantles the pro-CAF programs in pancreatic ductal adenocarcinoma (PDAC) to avoid its progression.
Lysine demethylase 4C (KDM4C) is a chromatin-modifying protein frequently overexpressed across multiple solid and hematological cancers (including breast, lung, colon, prostate, esophageal cancers and lymphomas) and has been linked to chromatin instability and enhanced cell proliferation and stem cell-like behavior.
Nagoya University Graduate School of Medicine (Japan) and collaborating institutions aimed to characterize the heterogeneity of myofibroblastic cancer-associated fibroblasts (CAFs) in pancreatic ductal adenocarcinoma using the KPC mouse model.
Akari Therapeutics plc has released new preclinical data indicating the therapeutic potential of AKTX-101 in pancreatic cancer driven by KRAS mutations. AKTX-101 is an antibody-drug conjugate (ADC) that delivers a novel RNA spliceosome modulating payload, PH1, into cancer cells that express TROP2.
Researchers from Prospect Therapeutics Inc. have discovered PSTA-5204, a novel oral KRAS G12D(ON) inhibitor that exhibits potent in vitro activity, strong in vivo efficacy and high selectivity over wild-type KRAS.
A team from the University of Missouri and collaborating institutions aimed to investigate the role of ABTB2 expression in pancreatic ductal adenocarcinoma cells. To do that, they applied a comprehensive suite of functional genomics tools, including siRNA/shRNA knockdown, CRISPR-Cas9 knockout, plasmid-based overexpression and a Cre-LoxP transgenic mouse model to modulate ABTB2 expression.
Tango Therapeutics Inc. plans a pivotal study next year in second-line MTAP-deleted pancreatic ductal adenocarcinoma based on positive phase I/II data with next-generation MTA-cooperative PRMT5 inhibitor vopimetostat (TNG-462) in patients with tumors of that type.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadly forms of cancer, with a 5-year relative survival rate of only 13%. To understand cell fate decisions and progression in PDAC, it is crucial to clarify the communication networks between tumor cells.
Recurv Pharma Inc. has developed a novel taxoid compound formulated in an oil-in-water nanoemulsion, named RP-001, as a potential therapeutic approach for the management of pancreatic ductal adenocarcinoma (PDAC), either as a single agent or combined with immune checkpoint inhibitors.
